Read-only by design — Olmem never buys, sells, shorts, or places any order. This platform provides market research and decision-support tools only. It does not provide personalized financial advice, does not guarantee investment results, and does not execute trades. All investment decisions are the responsibility of the user.
O
← Scanner

REGNRegeneron Pharmaceuticals, Inc.

Healthcare·Biotechnology·NASDAQ·Mkt cap $90.00B
$663.10
-$1.46 (-0.22%) today
IEX feed · not consolidated
Last updated Jul 14, 10:11 AM
63/100 Opportunity
34Risk
74Momentum
88Pullback
65Quality
68Valuation
37Trend
Price & History (up to 5 years)
→
Low 0.00— support · — resistanceHigh 0.00
Technical Indicators
RSI (14)58.7
MACD hist6.52
ATR (14)15.13
SMA 20634.29
SMA 50648.30
SMA 200700.74
Rel volume0.8x
Boll upper678.89
Boll lower589.70
52w high817.55
52w low538.57
5y high1,199.78
5y low474.96
Hist. vol33%
Max drawdown-26%
Long-Term UptrendBuy WatchPossible Dip BuyEntry: Near Support
Company QualityStable
Revenue growth+8.0%
Earnings growth+10.0%
Profit margin+16.0%
ROE+20.0%
Debt/Equity0.60
Free cash flow—
P/E22.0
Fwd P/E18.0
P/S4.0
P/B4.5
Div yield+1.5%

Regeneron Pharmaceuticals, Inc. — Biotechnology company in the Healthcare sector.

Decision SummaryInternal Rule-Based Analysis
Current Rating
Neutral / Needs Confirmation
Opportunity Score
63/100
Risk Level
Low-Moderate
Best Action
Monitor for entry confirmation near support

Why: REGN is trading near recent levels (-0.2% today). Overall, the company is reasonably solid. The long-term trend remains up. Price is holding above key moving averages with constructive structure. This may be worth monitoring, but confirmation is needed before acting.

What to watch: Volume confirmation, hold of nearest support, next earnings date, sector strength, and news sentiment.

Avoid if: Price breaks below support on heavy volume or company guidance weakens.

Internal Rule-Based Analysis · Learning From Historical Outcomes. This rating comes from Olmem’s internal scoring and historical pattern tracking. It is not a guaranteed prediction.

Research only — not financial advice. Olmem never executes trades.

All Scores
Company Quality65
Historical Context68
Valuation68
Trend37
Momentum74
Pullback88
News Sentiment50
Business Move50
Sector Strength55
Risk/Reward72
Entry Timing80
Sell Risk42
Risk34

News & business-move scores come from Olmem’s rule-based news engine (keyword-classified headlines) — no AI. They default to a neutral 50 when there is no recent news.

Recent NewsLive headlines

Real headlines from across the web. By default Olmem reads them with its rule-based news engine (keyword-classified — no AI) to set the News Sentiment score. Connect your own AI provider to have it read these actual headlines in the AI Stock Explanation.